GSTM1 and chronic kidney disease: The KDIGO (Kidney Disease: Improving Global Outcomes) guidelines recommend that patients with stage 5 CKD receiving dialysis should start ESA therapy when their Hb level is between 9.0 and 10.0 g/dL to prevent the concentration from decreasing to <9.0 g/dL.3